▶ PINEALON · SUBTOPIC · SAFETY PROFILE
PINEALON Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of PINEALON.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of PINEALON. Severity, frequency, and attribution depend on the source publication.
- Generally well-tolerated in preclinical and small Russian clinical studies
- Limited Western safety data
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for PINEALON.
- Largely unstudied
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for PINEALON in the published record:
- Pregnancy/lactation (unstudied)
- Hypersensitivity
FDA REGULATORY STATUS
Not FDA-approved. Research-use only in the United States.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ Is Pinealon FDA-approved?
No. Research-use only in the United States.
▶ Is Pinealon WADA-prohibited?
Pinealon is not currently listed on the WADA Prohibited List as of 2026.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Khavinson VK, Kuznik BI, Tarnovskaya SI. Short peptides and gene regulation in aging. Bull Exp Biol Med 2012. link
- Khavinson VK et al.. Neuroprotective effects of Khavinson's short peptides in stress models. Bull Exp Biol Med 2014. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25